Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
LAP3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of LAP3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
LIPE Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of LIPE sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
LMTK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of LMTK2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
LATS2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of LATS2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
LMLN Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of LMLN sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
KY Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KY sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
KCNV1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNV1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
KDM8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KDM8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
KCNU1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNU1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
KCNV2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNV2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
KCNS1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNS1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
KCNT2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNT2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
214
215
216
217
218
>>
2926
>